Listeria Engineered To Support Aerobic Growth Using The Non-Mevalonate Pathway

Patent Status

Patent Pending

Brief Description

UC Berkeley researchers have developed variant Listeria bacteria that have one or more  nucleic acids that encode polypeptides required for isoprenoid synthesis through the non-mevalonate pathway, wherein the Listeria bacterium grows aerobically in the presence or absence of a functional mevalonate pathway. The Listeria strain can be used to induce enhanced activation and expansion of human gamma delta T-cells and have been shown to do so in vitro.  

Suggested uses

• therapeutics to induce robust expansion and activation of human gamma delta T-cells